Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to determine if a single injection of 1 or more dose
levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared
to placebo in participants with painful osteoarthritis (OA) of the knee.
Phase:
Phase 1
Details
Lead Sponsor:
Genascence Corporation
Collaborator:
California Institute for Regenerative Medicine (CIRM)